Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire

Galit Kleiner, Hubert H Fernandez, Kelvin L Chou, Alfonso Fasano, Kevin R Duque, Diana Hengartner, Albie Law, Adam Margolius, Yu-Yan Poon, Michel Sáenz Farret, Philip Saleh, Joaquin A Vizcarra, Glenn T Stebbins, Alberto J Espay, PSG NoMoFA Study Group, Galit Kleiner, Hubert H Fernandez, Kelvin L Chou, Alfonso Fasano, Kevin R Duque, Diana Hengartner, Albie Law, Adam Margolius, Yu-Yan Poon, Michel Sáenz Farret, Philip Saleh, Joaquin A Vizcarra, Glenn T Stebbins, Alberto J Espay, PSG NoMoFA Study Group

Abstract

Background: In patients with Parkinson's disease (PD), sleep, mood, cognitive, autonomic, and other non-motor symptoms may fluctuate in a manner similar to motor symptoms.

Objectives: To validate a final version of a patient-rated questionnaire that captures the presence and severity of non-motor fluctuations in levodopa-treated PD patients (NoMoFA).

Methods: We recruited PD subjects from five movement disorders centers across the US and Canada. We assessed the internal consistency, floor and ceiling effects, test-retest reliability, and concurrent validity of NoMoFA. Classical test theory and item response theory methods informed item reduction and Delphi process yielded a final questionnaire.

Results: Two hundred subjects and their care-partners participated in the study (age: 66.4 ± 9.6 years; disease duration: 9 ± 5.5 years; median Hoehn and Yahr [H&Y] OFF: 3 [range 1-5]; mean Unified Parkinson's Disease Rating Scale (UPDRS) III ON score: 27.4 ± 14.9). Acceptability of the scale was adequate. There were floor effects in 8/28 items. Cronbach's alpha was 0.894. While eight items had "item-to-total" correlations below the cutoff of 0.4, removing these items did not improve Cronbach's alpha. Test-retest reliability was acceptable (intraclass correlation coefficient [ICC] 0.73; 95% confidence interval, 0.64-0.80). Concurrent validity was adequate with all Spearman's rho values comparing NoMoFA score to other measures of parkinsonian severity showing significance and in the expected direction. A final Delphi panel eliminated one item to avoid redundancy.

Conclusions: The final 27-item self-administered NoMoFA is a valid and reliable questionnaire, capturing both static and fluctuating non-motor symptoms in PD. © 2021 International Parkinson and Movement Disorder Society.

Keywords: Parkinson's disease; non-motor fluctuations; non-motor symptoms; questionnaire; validation.

© 2021 International Parkinson and Movement Disorder Society.

References

    1. Witjas T, Kaphan E, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59(3):408-413.
    1. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
    1. Quinn N. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51:S25-S29.
    1. Martínez-Fernández R, Schmitt E, Martinez-Martin P, Krack P. The hidden sister of motor fluctuations in Parkinson's disease: a review on nonmotor fluctuations. Mov Disord 2016;31(8):1080-1094.
    1. Chaudhuri KR, Martinez-Martin P, Schapira AHV, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21(7):916-923.
    1. Goetz CC. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18(7):738-750.
    1. Martinez-Martin P, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Chaudhuri KR. Pilot study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). Mov Disord Clin Pract 2019;6:227-34.6(3):227-234.
    1. Kleiner-Fisman G, Martine R, Lang AE, Stern MB. Development of a non-motor fluctuation assessment instrument for Parkinson disease. Parkinsons Dis 2011;292719.
    1. U.S. Department of Health and Human Services: Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Clin Fed Regist 2009.
    1. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 2013.
    1. Taylor WJ, Schumacher HR, Baraf HSB, et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 2008;67(6):888-891.
    1. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
    1. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649-2653.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;(16):297-334.
    1. Loundsbury JW, Gibson LW, Saudargas RA. Scale development. In: Leong FTL, Austin JT, eds. The Psychology Research Handbook: A Guide for Graduate Students and Research Assistants. Thousand Oaks, CA: Sage Publications; 2006.
    1. Stevens JP. Applied Multivariate Statistics for the Social Sciences, 5th Edition. New York: Taylor & Francis Group; 2009.
    1. Maxwell SE, Kelley K, Rausch JR. Sample size planning for statistical power and accuracy in parameter estimation. Annu Rev Psychol 2008;59 537-563.
    1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30(12):1591-601.
    1. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53(4):695-699.
    1. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-2170.
    1. Hoehn MMYM. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
    1. Visser M, Marinus J, Stiggelbout AM, van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004;19(11):1306-1312.
    1. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Heal 1997;12(6):805-814.
    1. Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Park Relat Disord 2008;14(3):205-212.
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW Publication No. ADM 76-338. Rockville, MD: US Department of Health, Education and Welfare; 1976:383-406.
    1. DeVellis RF. Classical test theory. Med Care 2006;44(11 Suppl 3):S50-S59.
    1. Lord FM. Applications of item response theory to practical testing problems. Publisher: Lawrence Erlbaum Associates, Hillsdale NJ, 1980.
    1. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 1994;6:284-290.
    1. Curran PJ, West SG, Finch JF. The robustness of test statistics to nonnormality and specification error in confirmatory factor analysis. Psychol Methods 1996;1:16-29.
    1. Forero CG, Maydeu-Olivares A. Estimation of IRT graded response models: limited versus full information methods. Psychol Methods 2009;14:275-299.
    1. Hays RD, Morales LS, Reise SP. Item Response Theory and health outcomes measurement in the 21st century. Med Care 2000;38 1128-1142.
    1. Kang T, Chen TT. Performance of the generalized S-X2 item fit index for the graded response model. Asia Pacific Educ Rev 2011;45 391-406.
    1. Chaudhuri KR, Schrag A, Weintraub D, et al. The Movement Disorder Society Nonmotor Rating Scale: initial validation study. Mov Disord 2020;35(1):116-133.
    1. Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007;22(13):1901-11.
    1. Storch A, Schneider CB, Klingelhöfer L, et al. Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). J Neural Transm 2015;122(12):1673-84.
    1. Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson's disease. Semin Neurol 2017.
    1. Stebbins GT. Clinical rating scale development. In: C. Sampaio CGG& AS, ed. Park Dis Rat Scale. New York, NY: Oxford University Press, Inc.; 2012.
    1. Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. New York, NY: McGraw Hill; 2010.
    1. Safarpour D, Thibault DP, Desanto CL, et al. Nursing home and end-of-life care in Parkinson disease. Neurology 2015;85(5):413-19.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe